Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis

A Review of the Literature and Case Report

Kristin C. Sokol, Aasia Ghazi, Brent Kelly, J. Andrew Grant

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Patients with all forms of mastocytosis can experience urticaria, abdominal cramps, nausea, diarrhea, or hypotension due to release of mediators by mast cells. Patients with mastocytosis and Hymenoptera venom allergy can develop severe adverse reactions to Hymenoptera stings. In addition, patients with mastocytosis and on venom immunotherapy are at high risk for incomplete protection and fatal reactions. Recent literature has reported the use of omalizumab as an adjunctive treatment in patients with mastocytosis, used for both symptom improvement and to dampen adverse effects caused by venom immunotherapy. This article reviews the literature regarding omalizumab use in the treatment of mastocytosis and for protection against the adverse effects during venom immunotherapy. In addition, we report the case of a patient at high risk and with cutaneous mastocytosis, whose symptoms improved with concomitant administration of omalizumab and venom immunotherapy.

Original languageEnglish (US)
Pages (from-to)266-270
Number of pages5
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume2
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Mastocytosis
Venoms
Immunotherapy
Hymenoptera
Cutaneous Mastocytosis
Therapeutics
Colic
Urticaria
Bites and Stings
Mast Cells
Hypotension
Nausea
Diarrhea
Hypersensitivity
Omalizumab

Keywords

  • ACE (angiotensin converting enzyme)
  • Hymenoptera allergy
  • Mastocytosis
  • Omalizumab
  • Telangiectasia macularis eruptiva perstans
  • Venom immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Medicine(all)

Cite this

Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis : A Review of the Literature and Case Report. / Sokol, Kristin C.; Ghazi, Aasia; Kelly, Brent; Grant, J. Andrew.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 2, No. 3, 2014, p. 266-270.

Research output: Contribution to journalArticle

@article{36339939b14b4840b86b5fdb02de2111,
title = "Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis: A Review of the Literature and Case Report",
abstract = "Patients with all forms of mastocytosis can experience urticaria, abdominal cramps, nausea, diarrhea, or hypotension due to release of mediators by mast cells. Patients with mastocytosis and Hymenoptera venom allergy can develop severe adverse reactions to Hymenoptera stings. In addition, patients with mastocytosis and on venom immunotherapy are at high risk for incomplete protection and fatal reactions. Recent literature has reported the use of omalizumab as an adjunctive treatment in patients with mastocytosis, used for both symptom improvement and to dampen adverse effects caused by venom immunotherapy. This article reviews the literature regarding omalizumab use in the treatment of mastocytosis and for protection against the adverse effects during venom immunotherapy. In addition, we report the case of a patient at high risk and with cutaneous mastocytosis, whose symptoms improved with concomitant administration of omalizumab and venom immunotherapy.",
keywords = "ACE (angiotensin converting enzyme), Hymenoptera allergy, Mastocytosis, Omalizumab, Telangiectasia macularis eruptiva perstans, Venom immunotherapy",
author = "Sokol, {Kristin C.} and Aasia Ghazi and Brent Kelly and Grant, {J. Andrew}",
year = "2014",
doi = "10.1016/j.jaip.2014.03.009",
language = "English (US)",
volume = "2",
pages = "266--270",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis

T2 - A Review of the Literature and Case Report

AU - Sokol, Kristin C.

AU - Ghazi, Aasia

AU - Kelly, Brent

AU - Grant, J. Andrew

PY - 2014

Y1 - 2014

N2 - Patients with all forms of mastocytosis can experience urticaria, abdominal cramps, nausea, diarrhea, or hypotension due to release of mediators by mast cells. Patients with mastocytosis and Hymenoptera venom allergy can develop severe adverse reactions to Hymenoptera stings. In addition, patients with mastocytosis and on venom immunotherapy are at high risk for incomplete protection and fatal reactions. Recent literature has reported the use of omalizumab as an adjunctive treatment in patients with mastocytosis, used for both symptom improvement and to dampen adverse effects caused by venom immunotherapy. This article reviews the literature regarding omalizumab use in the treatment of mastocytosis and for protection against the adverse effects during venom immunotherapy. In addition, we report the case of a patient at high risk and with cutaneous mastocytosis, whose symptoms improved with concomitant administration of omalizumab and venom immunotherapy.

AB - Patients with all forms of mastocytosis can experience urticaria, abdominal cramps, nausea, diarrhea, or hypotension due to release of mediators by mast cells. Patients with mastocytosis and Hymenoptera venom allergy can develop severe adverse reactions to Hymenoptera stings. In addition, patients with mastocytosis and on venom immunotherapy are at high risk for incomplete protection and fatal reactions. Recent literature has reported the use of omalizumab as an adjunctive treatment in patients with mastocytosis, used for both symptom improvement and to dampen adverse effects caused by venom immunotherapy. This article reviews the literature regarding omalizumab use in the treatment of mastocytosis and for protection against the adverse effects during venom immunotherapy. In addition, we report the case of a patient at high risk and with cutaneous mastocytosis, whose symptoms improved with concomitant administration of omalizumab and venom immunotherapy.

KW - ACE (angiotensin converting enzyme)

KW - Hymenoptera allergy

KW - Mastocytosis

KW - Omalizumab

KW - Telangiectasia macularis eruptiva perstans

KW - Venom immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84899745375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899745375&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2014.03.009

DO - 10.1016/j.jaip.2014.03.009

M3 - Article

VL - 2

SP - 266

EP - 270

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 3

ER -